{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '4.', 'INTRODUCTION', '4.1.', 'Background Information', 'Rhinitis is defined as inflammation of the nasal membranes and is characterized by the presence', 'of the following: nasal congestion, rhinorrhea, sneezing, nasal itching, and nasal obstruction.', 'Allergic rhinitis (AR) is the most common cause of rhinitis and represents a global health', 'problem affecting approximately 10% to 30% of the general adult population and its prevalence', 'is increasing worldwide (Tran et al, 2011; Naclerio et al, 2010). In the United States (US), AR', 'affects 10% to 30% of the adult general population and up to 40% of children. This accounts for', '30 to 60 million people in the US. In the US, the direct medical costs (eg, physician services,', 'diagnostics, medications) increased approximately 2-fold from US $6.1 billion in 2000 to US', '$11.2 billion in 2005 (Tran et al, 2011).', 'The high frequency of AR and prevalence in children underscores the importance of AR in', 'health care because the condition can result in absenteeism, diminished learning capacity, and an', 'overall poorer quality of life at school and at home (Jauregui et al, 2009; Blaiss, 2008; Nathan,', '2007; Lai et al, 2005). The comprehensive Pediatric Allergies in America survey estimates an', \"almost 30% loss in productivity on a child's most symptomatic days (Meltzer et al, 2009).\", 'Further, according to the American Academy of Allergy, Asthma, and Immunology task force on', 'allergic disorders, more than 2 million missed school days are attributed to AR each year', '(Baena-Cagnani and Patel, 2010). Children with AR tend to be more limited in their activities.', 'Further, improperly managed AR may contribute to the worsening of comorbid conditions,', 'including asthma, rhinosinusitis, and otitis media, in pediatric subjects (Baena-Cagnani and', 'Patel, 2010).', 'Allergic rhinitis (AR) has been traditionally subdivided into seasonal, perennial, and', 'occupational rhinitis and involves the inflammation of the mucous membranes of the nose, eyes,', 'eustachian tubes, middle ear, sinuses, and pharynx. Inflammation of the mucous membranes is', 'characterized by a complex interaction of inflammatory mediators but ultimately is triggered by', 'an immunoglobulin E (IgE)-mediated response to extrinsic proteins, such as pollens or molds', '(food allergies rarely cause AR, except as part of a multiorgan reaction) (Kaliner et al, 2010;', 'Min, 2010; Rosenwasser et al, 2005). When 2 or more symptoms such as watery rhinorrhea,', 'sneezing, nasal obstruction, and nasal pruritus persist for 1 hour or more, AR is strongly', 'suspected.', 'After allergens are inhaled into the nasal mucosa of sensitized subjects, they bind to IgE on the', 'surface of mast cells, resulting in aggregation of IgE receptors (FccRI) and the release of', 'chemical mediators including histamine. Binding of histamine to the H1 receptor increases', 'paracellular permeability, which contributes to the early-phase response of AR, characterized by', 'sneezing, rhinorrhea, and nasal congestion. Infiltration of inflammatory cells (activated', 'eosinophils and T-helper type 2 cells) into the nasal mucosa is induced by chemo-attractant', 'factors (including various cytokines) and results in edema of the nasal mucosa. This', 'inflammation, the late-phase response of AR, develops 6 to 10 hours after allergen challenge and', 'causes prolonged nasal congestion (Okano, 2009).', 'Many pharmacologic agents are available to treat AR. They target different symptoms and', 'include oral antihistamines, intranasal corticosteroids, intranasal antihistamines, decongestants,', 'Glenmark', 'CONFIDENTIAL', 'Page 18 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'mast cell stabilizers, leukotriene modifiers, anticholinergics, and allergen immunotherapy', '(Tran et al, 2011; Nasser et al, 2010; Shapiro and Nassef, 2005). Systemic antihistamines', 'generally do not provide the degree of targeted relief of nasal sprays (NSs)', '(Prenner and Schenkel, 2006). Topical (intranasal) antihistamines (H1 receptor antagonists) are', 'prescribed to treat the nasal itch, sneezing, and rhinorrhea caused by the release of histamine and', 'inflammatory mediators due to the allergic reaction (Okano, 2009). Intranasal corticosteroids', 'inhibit both early and late reactions and reduce IgE production and eosinophilia by inhibiting the', 'secretion of cytokines including interleukin (IL)-4 IL-5, and IL-13 (Okano, 2009; Rosenwasser', 'et al, 2005).', 'Medicinal options for children suffering with seasonal allergic rhinitis (SAR) include intranasal', 'antihistamines (eg, azelastine hydrochloride and olopatadine hydrochloride), oral (prescription or', 'over the counter) second-generation antihistamines (eg, levocetirizine, cetirizine, desloratadine,', 'loratadine, and fexofenadine), intranasal corticosteroids (eg, beclomethasone, budesonide,', 'ciclesonide, fluticasone furoate, fluticasone propionate, triamcinolone acetonide, flunsolide, and', 'mometasone furoate), and oral leukotriene receptor antagonists (montelukast)', '(Meltzer et al, 2011). Some of these products are also approved for the treatment of perennial', 'allergic rhinitis (PAR) in children, but the approved age range varies among these treatment', 'options.', 'The ideal therapeutic agent for managing the symptoms of AR effectively addresses the', 'pathophysiology of both the early-phase reaction and the late phase reaction of the condition', '(Spector, 1999). It is hypothesized that 2 agents with different mechanisms of action could have', 'the potential for a greater effect when used in combination than when used as monotherapies.', 'Currently, only 1 combination product containing an intranasal corticosteroid and intranasal', 'antihistamine (DYMISTA) is available for SAR treatment in subjects 6 years of age and older', '(DYMISTA USPI, 2015), but no such option is available for subjects suffering from perennial', 'AR in the United States of America (US) (DYMISTA USPI, 2015). GSP 301 nasal spray (NS)', 'is a FDC of an intranasal antihistamine (olopatadine hydrochloride) and corticosteroid', '(mometasone furoate) under clinical development for SAR in children and adults.', '4.2.', 'Description of Study Drug', 'Olopatadine is a histamine H1-receptor antagonist. Intranasal antihistamines have the potential', 'to provide quick symptomatic relief but do not provide substantial benefits for the late-phase', 'reaction of the allergic response that leads to nasal congestion. The antihistaminic activity of', 'olopatadine has been documented in isolated tissues, animal models, and humans', '(PATANASE USPI, 2012). It has been suggested that olopatadine is clinically superior to other', 'anti-allergy molecules because of its strong antihistamine activity and unique ocular mast cell', 'stabilizing properties (PATANASE USPI, 2012; Rosenwasser et al, 2005).', 'Mometasone is a corticosteroid demonstrating potent anti-inflammatory properties. Although', 'intranasal corticosteroids act on both early-phase and late-phase reactions, they have a slow onset', 'of action and can take hours to several days to reach their maximum benefit with some subjects', 'failing to achieve full relief of symptoms. The precise mechanism of corticosteroid action on AR', 'is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell', 'types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators', '(eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation', 'Glenmark', 'CONFIDENTIAL', 'Page 19 of 90']\n\n###\n\n", "completion": "END"}